3 Hotels and Commercial Property Company, Molecular Diagnostics Company and Precision Components Maker Stocks With a Strong Future Roadmap: Chalet Hotels, Molbio Diagnostics and MTAR Technologies

Hotel, diagnostics and precision part stocks give investors a way to track businesses that sit close to everyday demand in India. Chalet Hotels, Molbio Diagnostics and MTAR Technologies cover a hotels and commercial property company, a molecular diagnostics company and a precision components maker.

This list covers three hotel, diagnostics and precision part stocks with complete current figures: Chalet Hotels, Molbio Diagnostics and MTAR Technologies. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hotel, Diagnostics and Precision Part Stocks?

Hotel, diagnostics and precision part stocks are listed companies that own and operate premium hotels and commercial property, develop rapid molecular tests for infectious diseases, and make precision components for clean energy, space and defence programmes. Their earnings depend on room demand, testing volumes and programme orders.

Hotel, Diagnostics and Precision Part Stocks at a Glance

On valuation, Chalet Hotels trades at a P/E below the industry P/E, while Molbio Diagnostics and MTAR Technologies trade above it, which reflects the growth the market already expects. Readers comparing hotel, diagnostics and precision part stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Hotel, Diagnostics and Precision Part Stocks Have a Strong Roadmap in India?

Hotel, diagnostics and precision part stocks have a strong roadmap in India because strong business and leisure travel, wider access to molecular testing and growing clean energy and space programmes keep widening the market for these companies.

• Hotels. Premium travel fills city rooms.
• Molecular testing. Fast tests reach more clinics.
• Precision parts. Space and clean energy need exact tolerances.

Why Chalet Hotels Features Among These Hotel, Diagnostics and Precision Part Stocks

Among the hotel, diagnostics and precision part stocks on this list, Chalet Hotels owns and develops upscale hotels and resorts in key Indian cities such as Mumbai, Bengaluru and Hyderabad, and it also has a growing commercial and retail real estate portfolio. Its hotels operate under leading global brands.

Revenue rose from Rs 530 crore in FY22 to Rs 2,812 crore in FY26, a compound annual growth rate of 51.8%. Net profit grew from Rs 183 crore in FY23 to Rs 645 crore in FY26, which works out to a compound annual growth rate of 52.1%.

The company has a return on equity of 17.4%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 18,491 crore. The stock trades at a P/E of 35.0, below the industry P/E of 37.9.

Roadmap: The company is adding rooms at existing hotels and building new properties in cities where business and leisure travel is growing. Its annuity assets, such as office and retail space, add steady rental income alongside hotel earnings.

What to watch: Track occupancy, average room rates and the progress of new room additions.

Why Molbio Diagnostics Features Among These Hotel, Diagnostics and Precision Part Stocks

Among the stay, molecular testing and space part shares on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.

Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.

Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.

Why MTAR Technologies Features Among These Hotel, Diagnostics and Precision Part Stocks

Among the three companies on this list, MTAR Technologies is a Hyderabad-based maker of precision engineered components and assemblies for clean energy, nuclear, space and defence customers.

Revenue rose from Rs 331 crore in FY22 to Rs 899 crore in FY26, a compound annual growth rate of 28.4%. Net profit grew from Rs 60.9 crore in FY22 to Rs 94.0 crore in FY26, which works out to a compound annual growth rate of 11.5%.

The company has a return on equity of 11.4%, a debt to equity ratio of 0.46 and a market capitalisation of Rs 22,064 crore. The stock trades at a P/E of 165.4, above the industry P/E of 48.1.

Roadmap: The company supplies critical parts for fuel cell systems, space launch vehicles and nuclear power programmes, areas where qualification takes years and customer relationships are long-lasting. Added capacity and a growing order book support future revenue.

What to watch: Check order book execution in clean energy and the ramp-up of newly added capacity.

Chalet Hotels vs Molbio Diagnostics vs MTAR Technologies on Key Financials

The table below sets the three hotel, diagnostics and precision part stocks side by side on revenue, profit and margin, using reported figures.

Chalet Hotels posts the highest return on equity in this group at 17.4%. Chalet Hotels combines the largest FY26 revenue at Rs 2,812 crore with the fastest revenue growth, a 51.8% compound annual rate. A useful habit with hotel, diagnostics and precision part stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Hotel, Diagnostics and Precision Part Stocks

Every theme carries risks that deserve a check before any decision. For these hotel, diagnostics and precision part stocks, the main points are:

• Travel cycles. Bookings and occupancy follow travel demand.
• Order timing. Project awards can shift between periods.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hotel, diagnostics and precision part stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hotel, Diagnostics and Precision Part Stocks

Hotel, diagnostics and precision part stocks work best when investors track growth, valuation and return on equity side by side. Chalet Hotels, Molbio Diagnostics and MTAR Technologies each have a clear plan to grow. Based on the 9 November 2026 close, Chalet Hotels trades at Rs 818.25, Molbio Diagnostics at Rs 1,360.2 and MTAR Technologies at Rs 5,720.5.

Download the Univest iOS App or Univest Android App to track hotel, diagnostics and precision part stocks, set price alerts and get research-backed stock ideas.

What are hotel, diagnostics and precision part stocks?

Ans. Hotel, diagnostics and precision part stocks are listed companies that own and operate premium hotels and commercial property, develop rapid molecular tests for infectious diseases, and make precision components for clean energy, space and defence programmes. Their earnings depend on room demand, testing volumes and programme orders. This list looks at three of them, Chalet Hotels, Molbio Diagnostics and MTAR Technologies, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.

Which hotel, diagnostics and precision part stocks are covered in this list?

Ans. This list covers Chalet Hotels, Molbio Diagnostics and MTAR Technologies. Based on the 9 November 2026 close, Chalet Hotels traded at Rs 818.25, Molbio Diagnostics at Rs 1,360.2 and MTAR Technologies at Rs 5,720.5. Their return on equity ranges from 11.4% to 17.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 51.8%.

Why do hotel, diagnostics and precision part stocks have a strong future roadmap in India?

Ans. Hotel, diagnostics and precision part stocks have a strong roadmap in India because strong business and leisure travel, wider access to molecular testing and growing clean energy and space programmes keep widening the market for these companies. The main drivers are as follows. Hotels. Premium travel fills city rooms. Molecular testing. Fast tests reach more clinics. Precision parts. Space and clean energy need exact tolerances. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Chalet Hotels performed financially?

Ans. Revenue rose from Rs 530 crore in FY22 to Rs 2,812 crore in FY26, a compound annual growth rate of 51.8%. Net profit grew from Rs 183 crore in FY23 to Rs 645 crore in FY26, which works out to a compound annual growth rate of 52.1%. The company has a return on equity of 17.4%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 18,491 crore. The stock trades at a P/E of 35.0, below the industry P/E of 37.9. Looking ahead, the company is adding rooms at existing hotels and building new properties in cities where business and leisure travel is growing. Its annuity assets, such as office and retail space, add steady rental income alongside hotel earnings.

How has Molbio Diagnostics performed financially?

Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

How has MTAR Technologies performed financially?

Ans. Revenue rose from Rs 331 crore in FY22 to Rs 899 crore in FY26, a compound annual growth rate of 28.4%. Net profit grew from Rs 60.9 crore in FY22 to Rs 94.0 crore in FY26, which works out to a compound annual growth rate of 11.5%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.46 and a market capitalisation of Rs 22,064 crore. The stock trades at a P/E of 165.4, above the industry P/E of 48.1. Looking ahead, the company supplies critical parts for fuel cell systems, space launch vehicles and nuclear power programmes, areas where qualification takes years and customer relationships are long-lasting. Added capacity and a growing order book support future revenue.

What risks should investors check before buying hotel, diagnostics and precision part stocks?

Ans. Investors should check a few risks before buying hotel, diagnostics and precision part stocks. Travel cycles. Bookings and occupancy follow travel demand. Order timing. Project awards can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hotel, diagnostics and precision part stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.